CVE-2024-21257

Description

Vulnerability in the Oracle Hyperion BI+ product of Oracle Hyperion (component: UI and Visualization). The supported version that is affected is 11.2.18.0.000. Easily exploitable vulnerability allows low privileged attacker with access to the physical communication segment attached to the hardware where the Oracle Hyperion BI+ executes to compromise Oracle Hyperion BI+. Successful attacks require human interaction from a person other than the attacker. Successful attacks of this vulnerability can result in unauthorized read access to a subset of Oracle Hyperion BI+ accessible data. CVSS 3.1 Base Score 3.0 (Confidentiality impacts). CVSS Vector: (CVSS:3.1/AV:A/AC:L/PR:L/UI:R/S:U/C:L/I:N/A:N).

3.0
CVSS
Severity: Low
CVSS 3.1 •
EPSS 0.03%
Vendor Advisory oracle.com
Affected: Oracle Corporation Oracle Hyperion BI+
Published at:
Updated at:

References

Frequently Asked Questions

What is the severity of CVE-2024-21257?
CVE-2024-21257 has been scored as a low severity vulnerability.
How to fix CVE-2024-21257?
To fix CVE-2024-21257, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2024-21257 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2024-21257 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2024-21257?
CVE-2024-21257 affects Oracle Corporation Oracle Hyperion BI+.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.